MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2023 International Congress

    VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)

    H. Moes, E. Buskens, A. Portman, B. van Harten, M. van Kesteren, T. Mondria, L. Teune, E. van Wensen, M. van Onna, M. Schilperoord, A. Wertenbroek, M. Tjepkema-Cloostermans, L. Dorresteijn, T. van Laar (Groningen, Netherlands)

    Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…
  • 2023 International Congress

    Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson’s disease motor fluctuations

    S. Isaacson, G. Ceresoli-Borroni, A. Espay, R. Pahwa, P. Agarwal, H. Shill, J. Hui, K. Dashtipour, M. Lew, P. Qin, P. Lewitt (Boca Raton, USA)

    Objective: Evaluate safety/onset of efficacy during titration of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in U.S. outpatients with Parkinson’s disease (PD). Background: Global…
  • 2023 International Congress

    Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

    I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

    Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…
  • 2023 International Congress

    The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients

    O. Phokaewvarangkul, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma level of vitamin B and homocysteine between PD patients with conventional medications and PD patients with CSAI. Background: Although levodopa…
  • 2023 International Congress

    Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety

    SH. Isaacson, J. Kassubek, R. Pahwa, E. Pappert, S. Wu, C. Denecke Muhr (Boca Raton, USA)

    Objective: To compare the safety profile of clinic versus home dose optimization of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease experiencing OFF episodes.…
  • 2023 International Congress

    Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization

    W. Jost, M. Coelho, M. Fonseca, G. Castilla-Fernández, D. Magalhães, CK. Denecke Muhr (Wolfach, Germany)

    Objective: To assess the occurrence of orthostatic hypotension (OH) during apomorphine sublingual film (SL-APO) dose-optimization in patients with Parkinson’s disease (PwPD). Background: SL-APO has been…
  • 2023 International Congress

    Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study

    P. Alizadeh, V. Bruno, K. Naser, A. Abusarair, B. Achen (Calgary, Canada)

    Objective: To evaluate the effect and safety of subcutaneous apomorphine as a treatment for fluctuation-related pain in Parkinson's disease (PD). Background: Pain is one of…
  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease

    C. Happel, M. Grall, B. Lujan, A. Formella (Rockville, USA)

    Objective: To provide real-world experience regarding apomorphine treatment initiations with or without concomitant antiemetic prophylaxis. Background: Apomorphine hydrochloride (apo) injection, administered subcutaneously, is an “on-demand’…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Effect of marijuana on Essential Tremor: A case report
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Insulin dependent diabetes and hand tremor
      • Patients with Essential Tremor Live Longer than their Relatives
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley